Slide 1: Cover letter to BSE and NSE
July 3, 2020 Corporate Relationship Department Manager – Listing M/s. BSE Ltd M/s. National Stock Exchange of India Ltd Dalal Sreet, Fort “Exchange Plaza”, Bandra – Kurla Complex Mumbai 400 001 Bandra (E) Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir, Please find enclosed herewit
Slide 2: Natco Pharma Limited Investor Presentation Q4 2019-20
NATCO PHARMA LIMITED INVESTOR PRESENTATION Q4 2019-20
Slide 3: Disclaimer/Important Disclosure
DISCLAIMER/IMPORTANT DISCLOSURE THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background i
Slide 4: Business Overview
BUSINESS OVERVIEW Vertically integrated pharmaceutical company with presence across geographies - India, US and ROW Strong brand position in domestic pharma segments - Largest pharmaceutical player in oncology with brands catering to diseases including breast, bone, lung and ovarian cancer - Leading
Slide 5: Performance at a Glance
PERFORMANCE AT A GLANCE Revenue(1) ROE (%) Ownership Structure(3) INR mn 22,424 22,247 29% 20,789 20,224 23% Promoters, 10,897 48.93% 18% Public, 51.07% 12% 12% FY2016 FY2017 FY2018 FY2019 FY2020 EBITDA & EBITDA Margins 25.9% 33.5% 43.2% 41.6% 34.1% FY2016 FY2017 FY2018 FY2019 FY2020 INR mn 9,688 9,
Slide 6: Key Business Segments - Pharma
KEY BUSINESS SEGMENTS - PHARMA FORMULATIONS Domestic International Exports API (Domestic & Exports) Subsidiaries • Three key business segments: Oncology, ◼ Focused on niche opportunities in ◼ Strategically important division ◼ Operations in Brazil, Specialty Pharma, Cardiology and the US ◼ 39 active
Slide 7: US Market - Focus on Complex Generics
US MARKET- FOCUS ON COMPLEX GENERICS KEY PRODUCTS IN THE PORTFOLIO STRATEGY FOR US MARKETS Therapeutic Segment / Primary Key Brand Molecule ◼ Predominantly focused on high-barrier-to-entry products that are Indication Current Portfolio typically characterized by one or more of the following Copaxone
Slide 8: Strong Growth in Domestic Business
STRONG GROWTH IN DOMESTIC BUSINESS DOMESTIC PRODUCT LAUNCHES IN FY 2020 DOMESTIC FORMULATION SALES ◼ Launched 8 products during the year. Target to launch 6-8 products a year. INR mn ◼ Positioned #1 in sales of branded oncology medicines in India. ◼ Market leading positions across the Hep-C class of
Slide 9: Strong Market Position in Domestic Oncology Segment
STRONG MARKET POSITION IN DOMESTIC ONCOLOGY SEGMENT OVERVIEW OF ONCOLOGY DIVISION ONCOLOGY REVENUE ◼ Over 15 years of strong presence in oncology segment. One of the leaders in the sale of branded oncology medicines in India. INR mn 3,968 ◼ Portfolio of well recognized brands – 8 brands with INR 100
Slide 10: Expanding ROW Presence
EXPANDING ROW PRESENCE CANADA ◼ Strong portfolio with 20+ products including Oncology, cardiovascular and CNS therapies ◼ 18 approvals in place ◼ Several potential sole/limited generic products filed SUBSIDIARIES PERFORMANCE BRAZIL ◼ Sole generic of Everolimus tablets for the 2nd consecutive year IN
Slide 11: API Facilities
API FACILITIES STRENGTHS ◼ Strategically important business – develops APIs primarily for third party sales and also for captive ▪ Well established process safety engineering lab consumption ▪ Complex multi-step synthesis & scale-up ◼ Portfolio of 39 active US DMFs with niche products under developm
Slide 12: Research & Development Capabilities
RESEARCH & DEVELOPMENT CAPABILITIES R&D capabilities demonstrated by its complex and niche product filings in formulations and API segments ◼ Two research facilities with capabilities across synthetic chemistry, biotech & fermentation, nano pharmaceuticals, new drug FINISHED DOSAGE discovery & cell
Slide 13: Formulation Facilities
FORMULATION FACILITIES INTERNATIONAL MARKETS KOTHUR VISAKHAPATNAM ◼ Oral and solid dosages including ◼ Solid oral tablet and capsule cytotoxic Orals, cytotoxic manufacturing injectables and pre-filled syringes ◼ Site approval received from USFDA. First ◼ USFDA, GMP, (DCA), German, Health product app
Slide 14: Crop Health Sciences
CROP HEALTH SCIENCES TECHNICAL UNIT ◼ Strategically Initiated greenfield manufacturing facilities for producing Niche Agrichemical products in the Nellore District of Andhra Pradesh in January 2019 with a total capital expenditure of INR 100 crores ◼ Leveraging on our strengths in synthetic chemistr
Slide 15: Key Management
KEY MANAGEMENT V.C Nannapaneni ◼ Holds a Masters degree in Pharmaceutical Administration from the Long Island University, USA Chairman and Managing Director ◼ Over 4 decades of experience in the pharmaceutical industry Rajeev Nannapaneni ◼ Holds a Bachelors degree in Quantitative Economics and Histo
Slide 16: Consolidated Financials
CONSOLIDATED FINANCIALS Consolidated Profit & Loss Statement (INRmn) Consolidated Balance Sheet (INRmn) Particulars 31 March 2020 31 March 2019 Particulars 31 March 2020 31 March 2019 Income I ASSETS 1 Revenue from operations 19,150 20,945 (1) Non-current assets 2 Other income 1,074 1,302 (a) Proper
Slide 17: Quarterly Financial Summary
QUARTERLY FINANCIAL SUMMARY SEGMENTAL BREAKDOWN (INR MN) CONSOLIDATED FINANCIAL RESULTS (INR Mn) Revenue Division Q4FY2020 Q4FY2019 FY2020 FY2019 Q4 FY2020 Q4 FY2019 FY2020 FY2019 A) API Revenue:- 965 697 3,552 3,019 Total Revenues 4,772 4,867 20,224 22,247 B) Formulation:- B1) Formulation export an
Slide 18: Investor Relations Contact
Contact Investor Relations Team at ir@natcopharma.co.in 040-2354 7532; Extn 220 A VIEW OF THE ECO-PARK AT NATCO’S API FACILITY 17